Last Thursday, the DOJ did something we've been waiting decades for: Acting AG Todd Blanche signed an order moving FDA-approved cannabis products and any marijuana held under a qualifying state medical license from Schedule I to Schedule III.

That's real. That matters. But it's not the full picture — and if you're an operator, you need to understand what actually changed and what didn't before you start celebrating.

What Happened

The order covers two buckets. First, FDA-approved cannabis drugs — Epidiolex, Marinol, Syndros, Cesamet — are now Schedule III. Second, and more importantly for most of us, any cannabis product subject to a valid state-issued medical marijuana license also moves to Schedule III.

That second bucket is the one that matters. If you hold a state medical license and you're producing or distributing cannabis under that license, your product just dropped two schedules on the federal classification. The DEA is also creating an expedited registration pathway — a federal cannabis license — that uses your state medical license as proof of authorization.

Broader rescheduling hearings kick off June 29, 2026, with a deadline of July 15. That's when we find out whether the rest of the plant — including adult-use — gets the same treatment.

Why 280E Relief Is the Headline

For operators, the most immediate impact is tax relief. Section 280E of the Internal Revenue Code has been bleeding this industry dry since day one. Under Schedule I, cannabis businesses couldn't deduct standard expenses — rent, payroll, utilities, marketing — the things every other business in America writes off. You were paying effective tax rates of 60-70% in some cases.

Moving to Schedule III eliminates the 280E problem for covered medical products. That alone could be the difference between survival and shutdown for hundreds of operators who've been running razor-thin margins.

I've built and operated facilities that ran through the full 280E gauntlet. We structured deals and financials around that reality for years. Having that burden lifted — even partially — is a game-changer for business planning, investment attraction, and operational runway.

Banking Is About to Open Up

Schedule III also cracks open the banking door. The reason cannabis businesses have been running on cash and struggling to find banking partners isn't because banks don't want the business — it's because federal money laundering statutes made it a legal risk. With medical cannabis now in the same schedule as Tylenol with codeine, the compliance calculus changes completely.

Expect to see more traditional financial institutions willing to serve medical cannabis operators. That means real merchant processing, real lending, and real lines of credit. The capital infrastructure this industry has been missing is about to show up — slowly, but it's coming.

What Didn't Change

Let's be clear about what's still on the table:

Adult-use cannabis is still Schedule I under federal law. If you hold a recreational license and not a medical one, Thursday's order doesn't directly apply to you. You're still technically in violation of federal law, and 280E still applies to your operation.

Broader rescheduling could change that, but we're not there yet. The June hearings will be critical.

Also — rescheduling is not legalization. Even at Schedule III, cannabis is a controlled substance. You still need DEA registration. Interstate commerce is still restricted. Don't start shipping product across state lines because you read a headline.

What Operators Should Do Right Now

First, verify your license status. If you hold a state medical marijuana license, you're likely covered by this order. Talk to your compliance counsel and confirm.

Second, get your books in order. 280E relief means your tax strategy just fundamentally changed. If you've been filing under the old rules, you need to work with a cannabis-specialized CPA to restructure.

Third, start banking conversations. If you've been shut out of traditional banking, now is the time to reapproach. Bring the DOJ order, your state license, and a clean compliance record.

Fourth, watch the June hearings. If broader rescheduling passes, the entire competitive landscape shifts. Start planning for both scenarios.

The Bigger Picture

I've been in this industry for 28 years. I helped bring the first CBD import into Japan. I built ANVISA-authorized cannabis medicines in Brazil. I've cultivated 1,200+ acres of hemp under USDA Organic certification. Through all of that, the federal classification has been the single biggest barrier to building legitimate, scalable cannabis businesses.

This isn't the finish line. But it's the most significant federal policy shift we've seen in the history of this industry. Operators who move fast and position themselves correctly will have a massive advantage in the next 12-18 months.

We're watching this closely at HammerCG, and we're already advising clients on how to restructure around the new reality. If you need help navigating what this means for your operation, reach out.